Alkermes (ALKS) to Release Quarterly Earnings on Wednesday

Alkermes (NASDAQ:ALKS - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $0.42 per share and revenue of $343.20 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a return on equity of 27.52% and a net margin of 23.30%. The business had revenue of $306.51 million for the quarter, compared to analysts' expectations of $307.53 million. During the same period last year, the company posted $0.43 earnings per share. The business's quarterly revenue was down 12.6% on a year-over-year basis. On average, analysts expect Alkermes to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Up 1.2%

Shares of Alkermes stock traded up $0.35 during trading on Wednesday, reaching $29.20. The company's stock had a trading volume of 1,659,559 shares, compared to its average volume of 1,736,015. The business has a 50 day moving average price of $30.09 and a 200-day moving average price of $30.89. Alkermes has a 12-month low of $23.62 and a 12-month high of $36.45. The company has a market capitalization of $4.82 billion, a P/E ratio of 13.97, a price-to-earnings-growth ratio of 1.85 and a beta of 0.44.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ALKS shares. Cantor Fitzgerald upgraded shares of Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a research report on Thursday, March 27th. Robert W. Baird increased their target price on shares of Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Wall Street Zen lowered Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. Finally, UBS Group raised Alkermes from a "neutral" rating to a "buy" rating and raised their price objective for the company from $33.00 to $42.00 in a research note on Tuesday, June 17th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.92.

Insider Buying and Selling at Alkermes

In other news, SVP Christian Todd Nichols sold 3,334 shares of Alkermes stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the completion of the sale, the senior vice president owned 86,208 shares of the company's stock, valued at $2,680,206.72. The trade was a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Alkermes

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its position in Alkermes by 117.2% during the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock worth $9,098,000 after acquiring an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alkermes in the first quarter valued at $213,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Alkermes by 4.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company's stock valued at $15,927,000 after purchasing an additional 20,091 shares during the period. Hedge funds and other institutional investors own 95.21% of the company's stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.